PARSIPPANY, N.J. — Watson Pharmaceuticals Inc. is set to ship levonorgestrel and ethinyl estradiol birth control tablets.
The company said this week that its subsidiary, Watson Laboratories Inc., received approval from the Food and Drug Administration for levonorgestrel and ethinyl estradiol tablets 0.09 mg/0.02 mg.
According to Watson, the product is the generic equivalent to Pfizer’s Lybrel tablets.
Lybrel had total U.S. sales of almost $12 million for the 12 months ended April 30, 2011, according to IMS Health figures cited by Watson.
Lybrel tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception, Watson said.
